Tailored Therapy in Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT: Israeli H2 Study
Eldad J. Dann(Rambam Health Care Campus), Ora Paltiel(Hebrew University of Jerusalem), Rachel Bar‐Shalom(Rambam Health Care Campus), David Lavie(Hadassah Medical Center), Rosa Ruchlemer(Shaare Zedek Medical Center), Kalman Filanovsky(Kaplan Medical Center), Abraham Korenberg(Assaf Harofeh Medical Center), Marina Izak(World Health Organization Regional Office for South-East Asia), Ofer Shpilberg(Texas Oncology), Osnat Bairey(Tel Aviv University), Uri Abadi(Tel Aviv University), Luiza Akria(Western Galilee Hospital), Neta Goldschmidt(National Institutes of Health), Ron Epelbaum(University of Bern), Dina Ben Yehuda(Hadassah Medical Center), Dina Attias(Bnai Zion Medical Center), Elinor Sabbag(Rambam Health Care Campus), Roxolyana Abdah‐Bortnyak(Mansoura University), Netanel A. Horowitz(Rambam Health Care Campus)
Cited by 4
Related Papers
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells
|New England Journal of Medicine|2004|1.4k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k